期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 124, 期 1, 页码 47-55出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI69737
关键词
-
资金
- Novo Nordisk Foundation
- Danish Cancer Society
- Danish Strategic Research Foundation
- Novo Nordisk Fonden [NNF12OC0002209, NNF13OC0003435] Funding Source: researchfish
- The Danish Cancer Society [R72-A4666] Funding Source: researchfish
Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据